NFE2L2 and acute myeloid leukemia: Additionally, cells incubated with both drugs showed an increase in the ROS/GSH ratio and in KEAP1 and NQO1 expression levels suggesting that Oltipraz may not be a NRF2 activator, at least in AML cells.